Literature DB >> 17580136

Preischemic iloprost application for improvement of graft preservation: which route is superior in experimental pig lung transplantation: inhaled or intravenous?

T Wittwer1, U F Franke, T Sandhaus, M Thiene, J Groetzner, J T Strauch, J Wippermann, M Ochs, C Muehlfeld.   

Abstract

BACKGROUND: Optimal allograft protection is essential in lung transplantation to reduce postoperative organ dysfunction. Although intravenous prostanoids are routinely used to ameliorate reperfusion injury, the latest evidence suggests a similar efficacy of inhaled prostacyclin. Therefore, we compared donor lung-pretreatment using inhaled lioprost (Ventavis) with the commonly used intravenous technique.
METHODS: Five pig lungs were each preserved with Perfadex and stored for 27 hours without (group 1) or with (group-2, 100 prior aerosolized of iloprost were (group 3) or iloprost (IV). Following left lung transplantation, hemodynamics, Po(2)/F(i)o(2), compliance, and wet-to-dry ratio were monitored for 6 hours and compared to sham controls using ANOVA analysis with repeated measures.
RESULTS: The mortality was 100% in group 3. All other animals survived (P < .001). Dynamic compliance and PVR were superior in the endobronchially pretreated iloprost group as compared with untreated organs (P < .05), whereas oxygenation was comparable overall W/D-ratio revealed significantly lower lung water in group 2 (P = .027) compared with group 3.
CONCLUSION: Preischemic alveolar deposition of iloprost is superior to IV pretreatment as reflected by significantly improved allograft function. This strategy offers technique to optimize pulmonary preservation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580136     DOI: 10.1016/j.transproceed.2007.03.065

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study.

Authors:  Helene Haeberle; Stefanie Prohaska; Peter Martus; Andreas Straub; Alexander Zarbock; Gernot Marx; Manola Zago; Martin Giera; Michael Koeppen; Peter Rosenberger
Journal:  Trials       Date:  2020-03-04       Impact factor: 2.279

Review 2.  Intraoperative Circulatory Support in Lung Transplantation: Current Trend and Its Evidence.

Authors:  Henning Starke; Vera von Dossow; Jan Karsten
Journal:  Life (Basel)       Date:  2022-07-07

3.  Mesenchymal stem cell pretreatment of non-heart-beating-donors in experimental lung transplantation.

Authors:  Thorsten Wittwer; Parwis Rahmanian; Yeong-Hoon Choi; Mohamed Zeriouh; Samira Karavidic; Klaus Neef; Astrid Christmann; Tanja Piatkowski; Anke Schnapper; Matthias Ochs; Christian Mühlfeld; Thorsten Wahlers
Journal:  J Cardiothorac Surg       Date:  2014-09-02       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.